Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
or

Altimmune Inc (ALT)

Altimmune Inc (ALT)
6.65 +0.23 (+3.58%) 02/28/25 [NASDAQ]
N/A x N/A N/A x N/A
Realtime by (Cboe BZX)
N/A x N/A N/A x N/A
Realtime 6.50 -0.15 (-2.25%) 19:50 ET
Quote Overview for Fri, Feb 28th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
6.20
Day High
6.68
Open 6.24
Previous Close 6.42 6.42
Volume 3,370,900 3,370,900
Avg Vol 2,222,725 2,222,725
Stochastic %K 41.10% 41.10%
Weighted Alpha -40.17 -40.17
5-Day Change +0.22 (+3.42%) +0.22 (+3.42%)
52-Week Range 5.28 - 14.05 5.28 - 14.05
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 472,981
  • Shares Outstanding, K 71,125
  • Annual Sales, $ 430 K
  • Annual Income, $ -88,450 K
  • EBIT $ -100 M
  • EBITDA $ -102 M
  • 60-Month Beta 0.19
  • Price/Sales 22,831.13
  • Price/Cash Flow N/A
  • Price/Book 3.42

Options Overview Details

View History
  • Implied Volatility 90.21% ( +8.97%)
  • Historical Volatility 48.89%
  • IV Percentile 18%
  • IV Rank 16.94%
  • IV High 228.55% on 08/05/24
  • IV Low 62.00% on 02/12/25
  • Put/Call Vol Ratio 0.52
  • Today's Volume 11,605
  • Volume Avg (30-Day) 6,750
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 134,205
  • Open Int (30-Day) 118,989

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.37
  • Number of Estimates 5
  • High Estimate -0.33
  • Low Estimate -0.41
  • Prior Year -0.34
  • Growth Rate Est. (year over year) -8.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.80 +14.66%
on 02/25/25
Period Open: 6.93
7.18 -7.32%
on 01/29/25
-0.28 (-4.04%)
since 01/28/25
3-Month
5.80 +14.66%
on 02/25/25
Period Open: 8.73
10.88 -38.88%
on 12/04/24
-2.08 (-23.83%)
since 11/27/24
52-Week
5.28 +26.07%
on 08/05/24
Period Open: 13.28
14.05 -52.67%
on 02/29/24
-6.63 (-49.92%)
since 02/28/24

Most Recent Stories

More News
Altimmune Retail Buzz Heats Up On MASH Progress, FDA Nod For New Trials: Stock Jumps After Q4 Print

The company plans to unveil details at its virtual R&D Day on March 13.

ALT : 6.65 (+3.58%)
VTI : 292.96 (+1.54%)
IWM : 214.65 (+1.06%)
XBI : 88.71 (+1.85%)
Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

ALT : 6.65 (+3.58%)
Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors

ALT : 6.65 (+3.58%)
Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025

ALT : 6.65 (+3.58%)
Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference

ALT : 6.65 (+3.58%)
Why Altimmune Was Such a Robustly Healthy Stock on Thursday

Altimmune (NASDAQ: ALT) had some encouraging news to share with the world as the trading week drew near a close on Thursday. The biotech announced that it will soon ascend to an important, specialized...

ALT : 6.65 (+3.58%)
Altimmune, Inc. Added to Nasdaq Biotechnology Index Effective December 23, 2024

Altimmune, Inc. will join the Nasdaq Biotechnology Index on December 23, 2024, highlighting its progress and upcoming clinical milestones.Quiver AI SummaryAltimmune, Inc., a clinical-stage biopharmaceutical...

ALT : 6.65 (+3.58%)
Altimmune’s Nasdaq Biotech Index Addition Fuels Retail Enthusiasm, Stock Rebounds

The NBI serves as the basis for the iShares NASDAQ Biotechnology Index Fund and is reevaluated annually.

IBB : 137.03 (+1.14%)
ALT : 6.65 (+3.58%)
Altimmune Added to Nasdaq Biotechnology Index

ALT : 6.65 (+3.58%)
Altimmune, Inc. Announces Presentation of Pemvidutide Body Composition Data at International Conference on Sarcopenia and Cachexia

Altimmune's CMO will present Phase 2 trial data on pemvidutide for obesity at an upcoming conference in Washington, D.C.Quiver AI SummaryAltimmune, Inc. has announced that its Chief Medical Officer, Dr....

ALT : 6.65 (+3.58%)

Business Summary

Altimmune, Inc. is a clinical-stage immunotherapeutics company. It focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The company's proprietary platform technologies consist of RespirVec and Densigen. Altimmune Inc., formerly...

See More

Key Turning Points

3rd Resistance Point 7.29
2nd Resistance Point 6.98
1st Resistance Point 6.82
Last Price 6.65
1st Support Level 6.34
2nd Support Level 6.03
3rd Support Level 5.87

See More

52-Week High 14.05
Fibonacci 61.8% 10.70
Fibonacci 50% 9.66
Fibonacci 38.2% 8.63
Last Price 6.65
52-Week Low 5.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements